Us fda awards orphan drug designation (odd) to paxalisib for at/rt, a rare form of childhood brain cancer

Sydney , june 17, 2022 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia; asx: kza), an oncology-focused drug development company, is pleased to announce that the united states food and drug administration (fda) has awarded orphan drug designation (odd) to kazia's paxalisib for the treatment of atypical rhabdoid / teratoid tumors (at/rt), a rare and highly-aggressive childhood brain cancer. key points orphan drug designation (odd) is a special status accorded to drugs which are considered promising potential treatments for rare ('orphan') diseases, generally defined as those which affect less than 200,000 cases per annum in the united states.
KZIA Ratings Summary
KZIA Quant Ranking